Fresh analysis indicates that patients who stop using new GLP-1 drugs like Mounjaro or Wegovy may regain reduced body mass far faster than those who stop conventional lifestyle programs.
Published data in a major health publication demonstrates that while overweight people can lose substantial amounts of their body weight while on the medication, the mass returns at an average rate of nearly a kilo each month upon discontinuation.
"Users using such medications should be aware of the potential of quick rebound weight gain when the treatment concludes," stated expert Dr. Susan Jebb.
Such speed of regain suggests a reversion to starting weight within about 18 months.
Analyzing Treatments
The analysis, which reviewed 37 of trials involving thousands of participants, compared the outcomes of the injectable medications with conventional dieting.
The team note that people who shed pounds through lifestyle changes alone usually experience a less rapid weight regain—approximately 100 grams monthly—post-intervention.
Understanding the Quick Regain
Nutrition scientists suggest the way of the injections is key to understanding the amplified rebound.
GLP-1 drugs mimic a natural hormone called GLP-1, which helps regulate appetite.
"Sustained high doses of GLP-1 concentrations far above than normal might result in the body to generate a reduced amount of its own natural GLP-1, and could reduce responsiveness to its effects," explained Dr. Adam Collins, a nutrition expert.
"Withdrawal of this GLP-1 'fix' leads to appetite is uncontrolled, making binge eating far more likely."
A Chronic Condition?
Medical guidelines suggest the jabs for individuals with weight-linked health risks, alongside recommended diet and exercise modifications.
Professionals say that, considering the likelihood of relapse, the therapy is often ongoing.
This opinion is echoed by drug manufacturers, who say that the results "underscore the long-term nature of excess weight," akin to managing conditions like diabetes.
User Testimonies
Individuals who have come off the medication explain a intense resurgence of hunger.
"I experienced a switch flipping and you become starving," said a patient.
This challenge is exacerbated if patients have not established permanent dietary or behavioural changes during treatment.
Widespread Interest
Figures indicate that millions of adults in the UK have tried these injections in the past year, with demand remaining high.
- Adoption is greater among females compared to males.
- The 40s and 50s age group shows the highest usage rates.
- Many obtain the medications through private healthcare rather than public health services.
Finally, clinicians stress that while GLP-1 drugs are powerful tools for shedding pounds, they are not a standalone cure and maintained weight loss likely depends on combined lifestyle support.
